Current and Future Directions for Angiosarcoma Therapy

Vaia Florou, Breelyn A. Wilky

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Angiosarcomas are rare vascular neoplasms that are among the most aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in localized disease, as the infiltrative nature of these cancers leads to frequent local and metastatic recurrences. Cytotoxic chemotherapy, including anthracycline-based regimens and taxanes can produce significant responses in a subset of patients but durability is limited with most patients ultimately succumbing to metastatic disease. Targeted therapy with tyrosine kinase inhibitors is usually well-tolerated but prone to development of resistance. Few head-to-head trials have addressed the optimal sequence of therapies, or demonstrated conclusive benefits of one therapy over another based on clinical and etiologic factors. Novel therapies in clinical trials, including antibodies to endoglin and checkpoint inhibitors have demonstrated exciting early activity in patients with angiosarcoma. Improved understanding of the genetic heterogeneity within various angiosarcoma subtypes may identify predictive biomarkers to match patients to effective existing and future therapies. Overall, angiosarcoma patients with optimal performance status are best served in clinical trials that incorporate novel combinations of cytotoxic chemotherapy, targeted therapies, and immunotherapies.

Original languageEnglish (US)
Article number14
JournalCurrent treatment options in oncology
Issue number3
StatePublished - Mar 1 2018


  • Angiosarcoma
  • Chemotherapy
  • Clinical trials
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Current and Future Directions for Angiosarcoma Therapy'. Together they form a unique fingerprint.

Cite this